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Abstract 
Hepatic fibrogenesis may gradually result to cirrhosis due to the accumulation 
of extracellular matrix components as a response to liver injury. Thus, 
therapeutic decisions in chronic liver disease, regardless of the cause, should 
first and foremost be guided by an accurate quantification of hepatic fibrosis. 
Detection and assessment of the extent of hepatic fibrosis represent a 
challenge in modern Hepatology. Although traditional histological staging 
systems remain the “best standard”, they are not able to quantify liver fibrosis 
as a dynamic process and may not accurately substage cirrhosis. This review 
aims to compare the currently used non-invasive methods of measuring liver 
fibrosis and provide an update in current tissue-based digital techniques 
developed for this purpose that may prove of value in daily clinical practice.  
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1. Introduction 
Hepatic fibrosis is a central pathological healing process in progressive chronic 
liver disease. For many years, fibrosis was thought to be irreversible. The first 
notion on the regression of liver fibrosis appeared in the medical literature in 
1979, when Perez-Tamayo [1] analyzing the activity of liver collagenase, 
presented data supporting that cirrhosis could be reversible. During the last 
three decades, fibrosis has been widely accepted as a dynamic process with a 
strong potential for significant resolution. Substantial evidence originated from 
data showing that successful treatment of the underlying liver disorders, could 
reverse fibrosis and probably even cirrhosis [2-7]. Moreover, the understanding 
of cellular and molecular mechanisms of liver injury and insights in fibrogenesis 
led to the development of novel therapeutic approaches and advanced drug 
targets, especially for patients with chronic viral hepatitis B (CHB) or C (CHC). 
Scientific attention is currently focused on new anti-fibrotic therapies aiming at 
fibrosis reversibility and cirrhosis regression [3]. It is therefore important, now 
more than ever, to ensure accurate and prompt assessment of hepatic fibrosis 
in therapeutic trials of chronic liver disease. Liver biopsy still remains the 
reference for assessing fibrosis but it is now accepted that it is not a “gold 
standard”. The dynamic process of fibrosis should be best measured as a 
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continuous variable and classical histological staging systems do not permit 
this [8]. 
 
This review focuses on current histopathological and clinical challenges in the 
evaluation of liver fibrosis and aims to provide an update on invasive and non-
invasive methods for assessing the severity of hepatic fibrosis. Furthermore, 
the limitations of classical tissue-based staging systems and non-invasive 
markers, and the advantages of emerging digital techniques that permit a more 
precise assessment of hepatic fibrosis are discussed. 
 
2. Traditional Histological Staging Systems 
Liver biopsy incorporates information not only on fibrosis but also on 
inflammation, necrosis, steatosis, siderosis and other histopathological 
features with prognostic and predictive potential. Therefore, it still recognized 
as the "best standard" for the diagnosis and evaluation of fibrosis extent in 
chronic liver disease [8]. The first semi-quantitative histological scoring system 
was described in 1981 by Knodell and colleagues [9], who evaluated the 
features of chronic hepatitis and proposed the Histologic Activity Index (HAI). 
The HAI is an additive score calculated by summing semiquantitive scores for 
four individual features: periportal and/or bridging necrosis, hepatocyte 
7	
	
	
	
degeneration and/or focal necrosis, portal inflammation, and fibrosis. According 
to HAI, fibrosis is staged using a 5-tier system, with stage 0 corresponding to 
absence of fibrosis and stage 4 to cirrhosis. Intermediate stages 1 and 3 
correspond to fibrous expansion of portal tracts (score 1) and bridging fibrosis 
(score 3), respectively. In order to overstate the difference between mild and 
severe disease, Knodell and colleagues eliminated score 2 from their system. 
 
The histological staging systems that are currently in use all derive from the 
initial Knodell fibrosis score. These are either 5-tier (Scheuer, Batts-Ludwig, 
METAVIR, Brunt et al. and Kleiner et al.) [10-14] or 7-tier (Ishak et al) [15] and 
fibrosis is scored from 0-4 or 0-6, respectively (Table 1).  In the vast majority of 
clinico-pathological studies, liver biopsies with fibrosis score ≥2/4 are 
considered to have "clinically significant" fibrosis [12]; cirrhosis corresponds to 
the highest score and the last stage in all systems. 
 
3. Substaging of cirrhosis 
In 2000, Ian Wanless, then at the University of Toronto, Canada was the first to 
attempt sub-classifying cirrhosis [16]. His proposal was based on evidence that 
cirrhosis may substantially regress or may even be reversible in a variety of 
liver disorders. The Laennec scoring system, which is a modification of the 
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METAVIR system, subdivides stage 4 (cirrhosis) into three substages (4A, 4B 
and 4C), taking into consideration the width of the fibrous septa and the size of 
cirrhotic nodules. This histological subclassification is clinically important as 
now hepatologists recognize that all types of cirrhosis are not the same. A 
clinical subclassification of liver cirrhosis based on disease pathophysiology, 
hepatic venous pressure gradient (HVPG), and the compensation status of the 
cirrhotic patient was proposed in 2010 [17]. Indeed, histological sub-staging of 
the “last stage” correlates well with the clinical sub-stages of cirrhosis, the grade 
of portal hypertension [18,19], and patient prognosis [20]. 
 
4.  Noninvasive assessment of liver fibrosis 
In the past decade, several non-invasive methods for assessing hepatic fibrosis 
have been published, resulting in more non-invasive tests than there are 
histological scoring systems. The non-invasive tests were introduced to 
estimate the likelihood of advanced liver fibrosis in patients with chronic viral 
liver disease at presentation, and on follow-up to assess fibrosis regression 
post-treatment [21]. These tests were later applied in alcoholic (ALD) [22,23] 
and non-alcoholic fatty liver disease (NAFLD) [24-26]. There are three general 
categories of non-invasive tests for liver fibrosis: i) serologic panels or tests, ii) 
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combinations with other serum tests and/or clinical features (such as age and 
gender) in complex algorithms, and iii) imaging-based techniques [27]. 
 
Today, non-invasive methods are widely available. Their most important 
advantages are the absence of contra-indications and dangerous complications 
for the patients, and their reproducibility [28]. In contrast to liver biopsy, many 
non-invasive methods can effectively evaluate fibrosis extent in the whole 
organ and not only in a part of it. Their potential ability to identify and 
differentiate between advanced fibrosis stages, the high specificity and 
sensitivity to diagnose cirrhosis, and their easy application makes them a useful 
tool in daily clinical practice. Their role becomes more significant because their 
diagnostic accuracy can be increased if they are combined i.e. a serological 
panel may be used in conjunction with an imaging technique [29,30]. 
 
4.1. Serologic Panels 
The serologic fibrosis markers are broadly categorized into direct and indirect 
[28]. Direct markers of fibrosis include indices reflecting collagen synthesis or 
collagen degradation. The best validated marker is hyaluronic acid (HA), a 
glycosaminoglycan synthesized by hepatic stellate cells (HSCs) [31]. HA levels 
correlate with fibrosis in ALD [32] and chronic viral hepatitis [33-35] and a highly 
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negative score may be used in clinical practice as a reliable index for exclusion 
of fibrosis. Amino-terminal propeptide of type III collagen (PIIINP) is a marker 
associated with collagen deposition and its levels are increased in acute and 
chronic hepatic diseases [27]. Tissue inhibitors of metalloproteinases (TIMPs/ 
TIMP-1,TIMP-2), on the other hand, associated with the procedure of collagen 
degradation, which is a progressive to fibrosis consequence [27]. Indirect 
markers of fibrosis are simple routine blood tests reflecting alterations in liver 
function but not directly representing extracellular matrix metabolism. These 
biomarkers include indices related to portal hypertension (platelet count, spleen 
size), liver synthetic parameters (i.e. albumin), liver enzymes such as aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), AST/ALT ratio, 
gamma-glutamyltransferase (γ-GT), bilirubin and others (Table 2). They can be 
used in combination to produce serologic panels such as PGA and APRI, 
described below: 
 
PGA (Prothrombin time, γ-GT; Apoliprotein): PGA is one of the first biological 
indices used for the noninvasive detection of cirrhosis in alcoholic liver disease 
patients [36].  
	
11	
	
	
	
APRI (AST to Platelet Ratio Index): APRI is based on serum AST level and 
platelet count. It is calculated as (AST/upper limit of normal*) x100 ⁄ platelet 
count and has been extensively studied in patients with HCV or ALD [28,37]. 
*adjusted according to the reference values of each laboratory 
4.2. Combined scores and algorithms 
The long list of scores combining direct and indirect serum fibrosis markers and 
clinical data that have been developed and validated in recent years indicate 
the continuing need for increased accuracy in non-invasive evaluation of 
fibrosis. The currently used clinical combined scores, referred to also as 
‘’algorithms’’ are summarized below: 
 
Fibrotest® (Fibrosure® in the USA): It is the most studied and extensively 
validated algorithm. It involves five serum parameters (apolipoprotein-A, a2-
macroglubin, γ-GT, total bilirubin, aptoglobin) and takes into account patient 
age and gender. Fibrotest has been primarily used for patients with chronic viral 
hepatitis and is commercially available [38]. 
 
Hepascore: Four serum parameters (bilirubin, γ-GT, HA and a-2-
macroglobulin), patient age and gender are assessed in Hepascore, an 
algorithm mainly studied in chronic viral hepatitis. Hepascore can predict 
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fibrosis with a trustworthy AUROC 0.81 for significant fibrosis and 0.88 for 
cirrhosis [39]. 
 
Fibrospect: Fibrospect uses a combination of serum HA, tissue inhibitor of 
metalloproteinase-1 (TIMP-1) and a-2-macroglobulin, in order to discriminate 
patients with moderate or severe fibrosis from those without fibrosis, especially 
in CHC [40]. 
 
Fibrometer: Fibrometer includes six individual blood indices (platelet count, 
prothrombin index, AST, a-2-macroglobulin, HA, blood urea) and combines 
them to predict severe fibrosis in chronic viral hepatitis [41]. 
 
Forns score: Forns score derives from the combination of platelet count, γ-GT, 
cholesterol and patient age. It has been validated in CHC as well as in chronic 
hepatitis of non-viral aetiology [42]. 
 
European Liver Fibrosis panel (ELF): Score based on the combination of HA, 
TIMP-1 and amino-terminal propeptide of type III collagen. ELF has been 
studied in many different patient cohorts and has been proved to be a useful 
tool in various chronic liver diseases, especially in ALD and NAFLD [43]. 
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The combination of the APRI index with Fibrotest, a sequential algorithm 
referred to as "SAFE Biopsy" [44,45] (SAFE: Sequential Algorithm for Fibrosis 
Evaluation), can improve the diagnostic accuracy of the aforementioned 
panels, by detecting significant fibrosis (≥ F2 by METAVIR) and cirrhosis (F4) 
in CHC patients. The SAFE biopsy identified significant fibrosis and/or cirrhosis 
with >90% accuracy [44], moreover, it dismissed the need for liver biopsy in 
approximately 50% of the patients when it was used to identify significant 
fibrosis and in >80% when it was used to detect cirrhosis. The stepwise 
combination of APRI and Fibrotest with liver biopsy, in CHB patients, indicated 
that non-invasive tests and liver biopsy, when used together as agonists may 
improve diagnostic accuracy when assessing in the assessment of hepatic 
fibrosis [45]. 
 
BAAT score (BMI (Body mass index), Age, ALT, Triglyceride (TG) levels): This 
is the first index developed for the assessment of NAFLD fibrosis. It is 
calculated by summing four specific features, assigning 1 point for each of the 
following: BMI≥ 28 Kg/m2, age≥ 50 years, ALT≥ twice the normal values, and 
TG≥ 1.7mmol/Litre. According to Ratziu et. al, a score of 0 or 1 excludes 
significant fibrosis with NPV (Negative Predictive Value) of 100% [46]. 
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BARD score: BARD was validated in a cohort of NAFLD. It combines 3 
variables: AAR (AST/ALT ratio), BMI and the presence of type 2 diabetes. 
According to Harrison’s et al. a score 0 or 1 has a very high (96%) NPV for 
advanced fibrosis. However, as expected, variables such as obesity, diabetes 
and age, influence the score, resulting in a very low PPV (Positive Predictive 
Value) [47]. 
 
NAFLD fibrosis score: The NAFLD fibrosis score is calculated combining six 
variables using the following logistic formula: -1.675 + 0.037 age (years) + 
0.094 x BMI (kg/m2) + 1.13 x IFG/diabetes (yes =1, no = 0) + 0.99 x AST/ALT 
ratio - 0.013 x platelet (x109/l) - 0.66 albumin (g/dl). Values under the cut-off of 
-1.455 may exclude advanced fibrosis, whereas values higher than 0.676 are 
indicative of advanced fibrosis [48]. 
 
FIB-4 score: The FIB-4 score is one of the best validated non-invasive tests for 
the assessment of fibrosis in patients with advanced NAFLD [47,48]. According 
to a study of 541 patients with NAFLD fibrosis, FIB-4 score had a very high 
NPV (90%) in excluding and a satisfying PPV (80%) in diagnosing fibrosis. The 
calculating formula is: (Age x AST)/(Platelet count(x109)x√ALT). In daily clinical 
15	
	
	
	
practice, NAFLD score and FIB-4 are used to determine the necessity of liver 
biopsy in NAFLD patients [50]. 
 
4.3. Imaging techniques 
In recent years, a wide spectrum of imaging techniques, based on classical 
tools such as ultrasonography (U/S), computed tomography (CT) and magnetic 
resonance imaging (MRI) have improved the specificity for the detection and 
assessment of hepatic fibrosis. These include the following: 
 
Transient Elastography (TE) (Fibroscan®-Paris, France): TE is the most widely 
used imaging method for non-invasive and rapid measurement of hepatic tissue 
stiffness [51]. TE uses a probe that consists of an ultrasonic transducer and a 
vibrator that emits low-frequency shear waves (50 MHz) propagating into the 
liver tissue. The speed of the shear waves is directly related to liver tissue 
stiffness and units are expressed in kiloPascal (kPa). Many studies have 
evaluated the diagnostic accuracy of TE for diagnosing cirrhosis with specificity 
and sensitivity approaching 90%. The accuracy for fibrosis detection is lower, 
with sensitivity and specificity approaching 70-80% [52-54]. Obesity, ascites, 
acute inflammation, liver congestion, and elevated portal vein pressure may 
reduce TE accuracy because both adipose tissue and the presence of fluid may 
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influence the velocity of the shear wave [27,28,55]. Furthermore, a falsely 
increased liver stiffness, due to postprandial increase in portal vein pressure, 
has been observed [56,57]. 
 
Magnetic Resonance Elastography (MRE): MRE evaluates liver stiffness by 
measuring the propagation of mechanical waves [58]. These are produced by 
an active probe, placed on the patient’s back, directly over the liver. As a result, 
the magnetic scanner generates an elastogram, acting as a guide to 
quantify liver stiffness. MRE is superior to TE because of its ability to scan the 
whole organ and its application in patients with ascites or obesity. The main 
drawbacks are the high cost and complexity of the method that is too 
procrastinating for daily clinical practice. MRE values may be affected by the 
increased portal vein pressure following a meal, similar to TE [59]. 
 
Acoustic radiation force impulses (ARFI): ARFI uses conventional hepatic U/S 
to assess liver stiffness [60]. ARFI uses short duration acoustic pulses that 
produce mechanical excitation. The speed of the produced waves correlates 
directly with the extent of liver fibrosis and results are expressed in meter/sec 
(m/s). Advantages of this technology include the ability to select the area to be 
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assessed, avoiding large vessels or ribs [28] and the fact that steatosis does 
not influence the accuracy of the procedure. 
 
Real-time sonography-based Elastography: This method estimates the velocity 
of a shear wave through the liver using U/S and the results are expressed in 
kPa [61]. 
 
2D-Shear Wave Elastography (2D-SWE): 2D-SWE combines ultrasound 
images with radiation force induced into the liver. 2D-SWE can measure shear 
waves propagation in real time [62]. Advantages of 2D-SWE (expressed either 
in m/s or in kPa) include good applicability and adjustable region of interest 
depending on the operator.  
 
Contrast-Enhanced Sonography: This technique is based on intravenous 
injection of specifically sized microbubbles, transferred with a shell of protein or 
biopolymers that facilitate their sonographic imaging [63]. The time needed for 
the microbubbles to pass through the liver (hepatic vein transit time) is 
proportional to the underlying liver fibrosis and is lower in patients with cirrhosis. 
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Clinical research aims on gradually increasing the diagnostic ability of non-
invasive methods for assessing fibrosis; Castera et al [29] proposed an 
algorithm for decision making based on the combination of TE and Fibrotest 
in order to accurately evaluate fibrosis and cirrhosis. Using the algorithm for the 
diagnosis of significant liver fibrosis in patients with CHC [30], a large number 
of biopsies (approximately 75%) can be avoided. The combination of a serum-
based test with an imaging technique is another step in the continuous trial to 
improve the accuracy of non-invasive techniques. Although the use of these 
algorithms requires evolutional computerized systems they still remain a 
promising tool in clinical practice. 
        
5. Digital tissue-based methods for assessing liver fibrosis 
In the last decade, the increasing need for better diagnostic accuracy of tissue-
based methods for evaluating fibrosis has led to the development of digital 
tools. The most popular quantitative method for measuring the extent of fibrosis 
in Sirius red-stained liver tissue sections using computer-assisted digital image 
analysis (DIA) [64] is based on the evaluation of Collagen Proportionate Area 
(CPA) [65]. The equipment includes a digital camera connected to a personal 
computer and specific software using a grayscale slider that selects the overall 
tissue area and calculates this in pixels. Subsequently, with the aid of a red-
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green-blue threshold, the areas of Sirius red-stained collagen are also 
expressed in pixels. The "fibrosis ratio" between the two areas is expressed as 
the relative proportion (%) of collagen in the liver tissue or CPA. In order to 
eliminate image artifacts, fibrous tissue close to the liver capsule and large 
blood vessels is excluded from the measurements. 
 
CPA has been validated as an accurate tool for quantifying hepatic fibrosis in 
cirrhotic and non-cirrhotic patients. Importantly, CPA gains a place in the 
endeavor for accurate histological assessment of fibrosis as a continuous 
variable, in contrast to current histological staging systems, which assess 
fibrosis semi-quantitatively and assign non-continuous stages. Recent data 
show that CPA may assess patient prognosis as it predicts liver-related 
outcomes including clinical decompensating events [66,67]. In patients with 
recurrent hepatitis C after liver transplantation, CPA was shown to be more 
accurate in predicting fibrosis regression and clinical decompensation 
compared to Ishak staging [64]. In the same study, CPA significantly correlated 
with HVPG values. Independently of biopsy length, CPA showed a significant 
correlation with HVPG cut-off values that are diagnostically important; the ability 
of CPA to discriminate liver fibrosis progression and therefore to distinguish 
"early" from "late" cirrhosis was even greater in the lower HPVG values (early 
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portal hypertension). Thus, CPA and HVPG measurements could complement 
each other for a more accurate reflection of cirrhosis severity, supporting CPA 
as a superior tool to subclassify cirrhosis. 
 
6.    Steps in the future of tissue-based fibrosis evaluation 
Imaging data of supramolecular structures obtained by a multiphoton 
microscope is an innovative and much promising technique in modern 
pathology. It may be used to precisely quantify and score fibrillar collagen 
structures, without staining, using endogenous sources of nonlinear signals 
[68]. Two-Photon Excitation Fluorescence (TPEF) and Second Harmonic 
Generation (SHG) can be very helpful in this direction. Fibrillar collagen has the 
important biological property of a high crystalline triple-helix structure, which 
bereaves centrosymmetric organization at microscopic and mesoscopic scales. 
Second harmonic microscopy seems to be a major step ahead in the accurate 
evaluation of liver fibrosis by precisely quantifying non-stained fibrillar collagen 
and enabling the evaluation of fibrosis progression. 
 
A group of pathologists in France [69] scored fibrillar collagen deposits, using 
the Fibrosis-SHG index that describes the correlation between the evaluation 
of collagen deposits and the imaging data from the SHG signal. They 
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demonstrated a perfect correlation between the METAVIR fibrosis score and 
the Fibrosis-SHG index in different fibrosis stages (F0-F4). The study cohort 
included patients with CHB and/or CHC. The method allowed the discrimination 
not only between patients with advanced fibrosis versus cirrhosis but also 
between advanced fibrosis versus no fibrosis (F0-F1). Necroinflammation does 
not affect SHG scoring.  
 
Most recently, Xu et al devised a method based on the technology of 
SHG/TPEF [70]. They developed the “qFibrosis index” based on specific 
parameters of histopathological architectural features and the changes of 
collagen patterns. The method was applied in CHB patients. They employed a 
list of 87 collagen architectural features, categorized into three groups: septal 
collagen, portal collagen and fibrillar collagen. The samples were imaged in a 
SHG/TPEF technology-based microscope and the combination of pathology-
relevant collagen structures with the automated computer-assisted image 
analysis produced “qFibrosis index”; a trustworthy quantitative index, which 
could reliably recapitulate METAVIR staging scores. qFibrosis values increased 
proportionately with fibrosis progression and the differences between all stages 
were significant, indicating that “qFibrosis index” may be a useful tool in 
subcategorizing cirrhosis. Classical histological staging systems, such as 
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Knodell’s or Ishak’s, can be translated into qFibrosis, with the presupposition 
that they incorporate similar architectural features [65]. The accuracy of 
qFibrosis may be increased by co-implementing TPEF or other imaging 
techniques, in order to provide information not only on fibrosis but also on other 
histopathological features, such as necroinflammation and steatosis [70]. A 
recent study by J. Pirhonen et al. tested whether SHG microscopy is possible 
to be applied instead of routine histopathology grading systems, in the 
assessment of liver fibrosis in NAFLD patients. In this first description of SHG 
imaging in NAFLD, the automated SHG microscopy system seems to achieve 
an improvement in the sensitivity of detection of fibrosis in NAFLD with 
continuous grading, especially in early stages; importantly, this reference of 
SHG imaging technique utility, may be the basis of validation in a larger patient 
cohort (71). 
 
7. Overview and critical analysis 
Liver biopsy is an invasive and frequently painful procedure that may rarely be 
lead to dangerous complications, such as intraperitoneal bleeding and 
haemobilia, with a reported mortality of 0.009 to 0.12% [8,72,73]. Liver biopsy 
assesses a small tissue core corresponding to only about 1:50.000 of the whole 
organ, so there is a risk of under- or over-estimation of fibrosis in the entire 
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organ (sampling error) [74]. Other limitations include inter-observer variability 
and higher cost compared to most non-invasive techniques for fibrosis 
assessment [75,76]. 
 
The traditional histological staging systems are semi-quantitative methods, 
assigning numerical algorithms without quantitative relation to the underlying 
liver disease [77]. Despite their recognized value in routine histopathological 
practice they are inadequate to sub-classify cirrhosis [66]. Although all systems 
are well validated for everyday use they have potential disadvantages. In the 
Scheuer system [10], for example, differences between "enlarged portal tracts" 
(stage 1) and "periportal fibrosis" (stage 2) may be subtle and the pathologist 
may not recognize these with ease, while the meaning of "architectural 
distortion, but no obvious cirrhosis" is ambiguous. Furthermore, the inclusion of 
"periportal fibrosis" and "portal-portal septa formation" in the same category is 
a major drawback because only the latter is recognized as "clinically significant 
fibrosis" (≥F2 by METAVIR). All systems appoint "numerical" scores to each 
stage. However, the use of numerical calculations for a continuous variable, as 
is fibrosis, is now thought conceptually inexact, as already noted in the 
Introduction [77]. 
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On the other hand, there are many crucial issues regarding the use of non-
invasive tools. Serum markers of fibrosis are not liver-specific and they may be 
affected by the presence of other factors, such as inflammation; they actually 
represent the rate of matrix turnover and not matrix deposition. Therefore, it is 
inevitable that high inflammatory activity will result in increasing their values. 
Similarly, absence of inflammation may lead to underestimation of fibrosis 
[30,78-80]. In addition, serum markers are well validated only in chronic viral 
hepatitis (mostly in CHC and less in CHB) and less studied in ALD and NAFLD; 
in chronic liver disease of other aetiology they are still not validated [62]. 
Moreover, the fact that serum markers are surrogates and not biomarkers 
reduces their accuracy [27]. 
 
Novel imaging technology has increased accuracy for fibrosis evaluation. 
However, radiologic tests still have limitations. They give indeterminate results 
in 14%-33% of cases regarding the presence or absence of advanced fibrosis 
[27]. Imaging techniques are inaccurate in predicting intermediate stages of 
fibrosis [62]. Their high cost and limited local availability are additional 
limitations. Last but not least, most non-invasive tools have yet to be validated 
in routine clinical practice [30,78-80]. 
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The use of non-invasive methods may reduce the number of liver biopsies 
performed but still cannot completely replace the need for obtaining liver tissue 
for histological evaluation of fibrosis [8,81-83]. In cases of cirrhosis or no to 
minimal fibrosis, the stepwise combination of non-invasive tools can provide 
accurate results avoiding liver biopsy. However, in indeterminate cases in the 
“grey-zone”, it will always be necessary to perform a liver biopsy to accurately 
stage fibrosis [28,84]. 
Liver biopsy retains a significant role in hepatology for assessing liver fibrosis. 
The development of digital (CPA) and new innovative (SHG/TPEF, qFibrosis) 
tissue-based methods as objective and accurate staging tools has increased 
their value in recent years. Moreover, CPA has significant clinical applications, 
especially in assessing the response to anti-fibrotic therapies in cirrhotic 
patients. Initial clinical data show that cirrhosis can be accurately sub-classified 
using CPA. In addition, combination of CPA with other continuous variables, 
such as HVPG, may provide useful information for predicting decompensation 
in patients with recurrent hepatitis (66,67,84,86).  
Based on the above, CPA may be a better index of fibrosis progression and 
clinical outcome-predictor compared to TE [66,67]. In future studies, 
combination of CPA with TE may create a unique histological fibrosis index with 
increased accuracy. Hampering issues are mainly related to the application of 
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CPA in a rather small range of chronic liver diseases to date [87] and to the 
larger sample size required for DIA of CPA; the appropriate sample size for 
reliable CPA results varies from 22 to 28 mm², depending on liver disease 
etiology [88]. Although CPA seems to be of high value for further classifying 
cirrhosis, the non-standardized image analysis methods, the narrow 
applicability field in specific chronic liver diseases, the non-worldwide validation 
and the high cost-required for the equipment limit its clinical applicability to a 
degree [66,67,85]. 
 
SHG microscopy has all the advantages and but fewer limitations than CPA. It 
is fast and easy to perform since it does not require specific stains and its 
measurements are not affected by sample size [69]. SHG uses 3D imaging data 
of fibrillar collagen fibers overcoming the limitations of 2D imaging of a classical 
liver biopsy. In this way, SHG may evaluate extracellular matrix remodeling and 
may prove useful for assessing response to antifibrotic treatment and fibrosis 
regression. 
 
Similarly, qFibrosis may play a significant role in the near feature to assess 
cirrhosis and fibrosis regression in CHB patients treated with new long-term 
antiviral regimens [70]. The possible combination of qFibrosis with results of 
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other non-invasive tools, such as TE, could enhance the accuracy of the former 
in assessing liver fibrosis.  
 
8. Conclusion 
The scientific and clinical progress in our understanding of liver fibrosis provide 
hope for successful antifibrotic therapies in the near future. The accurate 
evaluation of liver fibrosis is of paramount importance to assess post-treatment 
regression; to achieve this ultimate goal, well validated methods of liver fibrosis 
assessment are required. Serum biomarkers, clinical algorithms and imaging 
techniques have become widely available and applied in clinical practice. Their 
significance in the evaluation of liver fibrosis for diagnostic and follow-up 
purposes in the era of direct acting antivirals is increasing. Digital tissue-based 
methods may prove invaluable in accurately assessing fibrosis 
progression/regression and architectural remodeling influencing treatment 
decisions in chronic liver disease. 
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Table 1.Traditional Histological Staging Systems 
  
Staging 
System 
Stage HistologicDescription Features Limitations 
Scheuer 
(8) 
 
0 
 
1 
 
2 
 
 
3 
 
 
4 
 
 
No fibrosis 
 
Enlarged portal tracts 
 
Periportal fibrosis± 
periportal septa 
 
Architectural distortion, but 
no obvious cirrhosis 
 
Cirrhosis 
(probableordefinite) 
 
Preferred for 
CHB and CHC 
 
Simple in 
routine practice 
Difficult distinction 
between stage 1 and 
stage 2. 
 
Unclear description  
of stage 3 
 
Inclusion of both 
periportal fibrosis and 
portal-portal septa in 
stage 2 
Batts-
Ludwig 
(9) 
0 
 
1 
 
2 
 
3 
 
 
4 
No fibrosis 
 
Portal/ periportal fibrosis 
 
Septal fibrosis 
 
Bridging fibrosis with 
architectural distortion 
 
Cirrhosis 
 
Simple, 
reproducible, 
validated in 
clinical practice 
 
Preferred for 
CHB and CHC 
No evaluation of 
regression/remodeling 
 
No evaluation 
"beyond" cirrhosis 
METAVIR 
(10) 
0 
 
1 
 
2 
 
 
3 
 
 
4 
 
 
No fibrosis 
 
Portal fibrosis without septa 
 
Few septa 
 
 
Numerous septa without 
cirrhosis 
 
Cirrhosis 
 
 
 
Simple, 
reproducible, 
validated in 
clinical practice 
 
Extensively 
used 
All systems appoint 
"numerical" scores to 
each stage 
 
Inappropriate use of 
numerical calculations 
for a continuous 
variable 
 
No evaluation of 
regression/remodeling 
 
No evaluation 
"beyond" cirrhosis 
Ishak et 
al (11) 
 
0 
 
1 
 
 
2 
 
 
3 
 
 
 
4 
 
 
 
No fibrosis 
 
Expansion of some portal 
areas with or without septa 
 
Expansion of most portal 
areas with or without septa 
 
Expansion of most portal 
tracts with portal-portal 
bridging 
 
Expansion of most portal 
tracts with portal-portal and 
portal-central bridging 
Preferred for 
research 
purposes 
 
 
Still 
reproducible 
and validated in 
clinical practice 
 
7-tier scale has 
more 
discriminant 
descriptive 
power 
 
Increased inter- and 
intra-observer 
variability 
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5 
 
 
6 
 
 
Bridging with occasional 
nodules 
 
Cirrhosis 
 
 
Laennec 
(12) 
 
 
 
 
 
 
 
0 
 
1 
 
2 
 
3 
 
4A 
 
4B 
 
4C 
 
 
No fibrosis 
 
Minimal fibrosis 
 
Mild fibrosis 
 
Moderate fibrosis 
 
Cirrhosis, mild or probable 
 
Cirrhosis, moderate 
 
Cirrhosis, severe 
 
 
 
Sub-staging of 
cirrhosis 
 
 
Histologic 
substages of 
cirrhosis are  
related to 
clinical cirrhosis 
stages 
 Limited validation 
 
Does not address 
disease aetiology 
 
Overlapping features 
within stage 3-4 
related to septal 
thickness 
 
Brunt et 
al (11) 
 
 
 
0 
 
1 
 
 
2 
 
 
 
3 
 
 
4 
 
 
No fibrosis 
 
Zone 3 (perisinusoidal, 
focal or extensive) 
 
Zone 3 as above and 
focal/extensive portal-
based fibrosis 
 
Same as 1 or 2 with 
bridging fibrosis 
 
Cirrhosis 
 
Developed for 
NASH 
 
 
Evaluation of 
central-based 
fibrosis 
 
Cannot be applied in 
simple NAFLD  
 
Cannot be applied in 
pediatric NAFLD  
 
No evaluation 
"beyond cirrhosis" 
 
NAFLD: Nonalcoholic fatty liver disease, NASH: Nonalcoholic steatohepatitis 
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Table 2. Non-invasive methods for assessment of liver fibrosis 
Direct serum 
markers 
Indirect serum 
markers/panels
Combined 
scores/Algorithms
Hyaluronic Acid  
Laminin 
YKL-40 
Procollagen type 
III (PIIINP) 
Metalloproteinases 
MMP-1,MMP-2 
TIMPs 
TGF-β1 
MP3 index 
AST/ALT 
 
γ-GT 
Platelet count 
Albumin 
PGA 
APRI 
 
Fibrotest® 
Hepascore® 
Fibrospect 
Fibrometer® 
Forns score 
ELF 
SAFE biopsy  
FIB-4 score 
NAFLD fibrosis 
score 
SAFE biopsy 
 
YLK-40: chondrex, human cartilage glycoprotein-39, PIIINP: Procollagen III 
amino terminal peptide, TIMPs: tissue inhibitors of metalloproteinases, TGF-
β1: Transforming growth factor-β, AST:  aspartate aminotransferase, ALT: 
alanine aminotransferase, γ-GT: gamma-glutamyl transferase, PGA: (P, 
prothrombin time; G, gamma-glutamyl transpeptidase; A, apoliprotein AI), 
APRI: AST to Platelet Ratio Index, ELF:  European Liver Fibrosis panel, 
SAFE: Sequential Algorithm for Fibrosis Evaluation, FIB-4 score: fibrosis-4, 
NAFLD: nonalcoholic fatty liver disease 
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Table 3. Αdvantages and limitations of liver biopsy and non-invasive methods 
for evaluation of fibrosis in chronic liver disease 
  Advantages   Limitations   
  
       
        
Liver biopsy Reference tool   
Histological staging assess fibrosis 
as a non-continuous variable  
  for assessing fibrosis       
      
Invasive procedure  with rare 
complications  
  Detailed information on liver       
  histopathology   
Sampling variability/ 
Involves only a small 
part of the whole organ   
          
      Inter/Intra-observer variability 
         
      Higher cost    
       
    
 
    
        
          
          
Non-invasive No contraindications   Not-liver specific  
methods         
  No complications   
Affected by other factors (e.g 
inflammation)  
          
  
Diagnostic accuracy for excluding 
cirrhosis/advanced fibrosis 
Direct markers assess matrix 
turnover/not deposition  
          
  Subclassify cirrhosis (CPA)  
Not widely validated in clinical 
practice and in a wide range of 
chronic liver disease (mainly in 
CHC)   
          
  High specificity   
Need validation in 
routine clinical practice   
          
  High sensitivity   
“Grey zone” 
(indeterminate results in 14%-33% of cases) 
          
  
Most are applicable 
in routine settings   
High cost and 
limited local 
availability for 
Imaging techniques    
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